Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435727 | 0.82 | LMNA (0.48) | CYP3A4CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL8904963 | 0.82 | LMNA (0.48) | CYP3A4CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL7769823 | 0.81 | KCNN4 (0.48) | KCNN4KCNA3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27439222 | 0.81 | SMN1; SMN2 (0.45) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL27350218 | 0.78 | KCNA5 (0.40) | SMN1; SMN2LMNAMEN1MAPTTSHR | |
| SCHEMBL7777404 | 0.78 | KCNN4 (0.46) | KCNN4KCNA3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5481230 | 0.77 | KCNN4 (0.50) | KCNN4KCNA3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16965599 | 0.76 | KCNN4 (0.50) | KCNN4KCNA3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15587141 | 0.75 | KCNN4 (0.46) | KCNN4KCNA3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15399429 | 0.71 | MEN1 (0.40) | SMN1; SMN2LMNAMEN1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037800-A1 | Method of treating neurological disorders using clotrimazole and derivatives thereof | ENVIVO PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2007002497-A1 | METHOD OF TREATING NEUROLOGICAL DISORDERS USING CLOTRIMAZOLE AND DERIVATIVES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037800-A1 | Method of treating neurological disorders using clotrimazole and derivatives thereof | HTT, HYPK, GRIK3 | KCNN4 2235/4885KCNA3 833/4885CYP1A2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.